Ironwood Pharmaceuticals Articles
EU approvals for Viread and Constella; EMA accepts vintafolide MAA
29 November 2012
AstraZeneca gains rights to sell Ironwood's IBS drug in China
24 October 2012
EMA backs Almirall's Constella; Bayer's Eylea recommended by CHMP
24 September 2012
FDA nod for use of Ironwood and Forest's Linzess in certain cases of IBS and constipation
3 September 2012
Almirall looks to robust 2012 despite higher losses
28 February 2012
Bionomics in $345 million CNS deal with Ironwood
6 January 2012
US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall
24 October 2011
FDA filings for Ironwood and Forest for linaclotide, and GSK and XenoPort for Horizant ER
10 August 2011
Almirall/Ironwood’s IBS drug linaclotide shows positive Ph III results
15 September 2010
Showing 1-10 of 10 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
